Welcome to our dedicated page for Serina Therapeutics news (Ticker: SER), a resource for investors and traders seeking the latest updates and insights on Serina Therapeutics stock.
Serina Therapeutics, Inc. (SER) news is centered on a clinical-stage biotechnology company developing the POZ Platform™ drug optimization technology and SER-252 for advanced Parkinson’s disease. Company updates often focus on clinical study progress, safety monitoring, tolerability observations, pharmacokinetic findings, and exploratory measures related to motor function.
The most important Serina news themes involve the Phase 1b registrational study of SER-252, including cohort dosing, Safety Monitoring Committee review, dose-escalation decisions, and observations tied to sustained apomorphine exposure. Because SER-252 is the company’s main named product candidate, clinical updates are closely tied to how the POZ Platform is being tested in a neurological disease setting.
Serina also reports financial results and business updates, securities financing activity, board and governance changes, and biotechnology conference participation. Research-related announcements may include POZ Platform applications across small molecules, RNA-based therapeutics, antibody-based drug conjugates, and lipid nanoparticle delivery formulations. Company materials also discuss partnership routes such as out-licensing, co-development, and a non-exclusive Pfizer license involving POZ polymer technology for lipid nanoparticle drug delivery formulations.
For SER stock research, key news categories include SER-252 clinical development, POZ Platform research, regulatory and financing disclosures, and corporate updates that affect how the company advances its wholly owned drug candidates and external platform applications.
Serina Therapeutics (NYSE American: SER) said NYSE American accepted its plan for continued listing compliance and granted a cure period through July 9, 2027. The company previously reported $1.6 million in stockholders' equity and multi-year losses. Serina will remain listed and face quarterly monitoring while it works to regain conformity; failure to comply could trigger suspension and delisting.
Serina Therapeutics (NYSE American: SER) reported full-year 2025 results and business highlights on March 25, 2026. Key items: FDA cleared an IND for SER-252 and the company dosed the first patient in a Phase 1b registrational trial for advanced Parkinson's disease. Serina secured financing, receiving $16.0M gross to date from a private placement and has raised $12.9M gross under an ATM program.
2025 operating expenses were $24.2M and net loss was $19.4M; cash totaled $3.1M at year-end.
Serina Therapeutics (NYSE American: SER) announced that CEO Steve Ledger will present in a fireside chat at the 38th Annual Roth Conference in Dana Point, CA on March 24, 2026 at 11:30 a.m. PST.
A live webcast is available to registered attendees and an archived replay will be accessible on-demand for 90 days following the event.
Serina Therapeutics (NYSE:SER) secured a private placement to raise $15 million in a first tranche, with a second tranche available for up to an additional $15 million, for total proceeds of up to $30 million. The financing includes 50% warrant coverage and potential additional proceeds of up to $33.3 million from warrant exercises, and is expected to extend runway into 2H 2027. Proceeds will support the ongoing single-ascending dose registrational arm of SER-252 under a 505(b)(2) NDA pathway; initial patient dosing has begun and topline SAD results target 1H 2027.
Serina Therapeutics (NYSE: SER) has dosed the first patient in a Phase 1b registrational trial of SER-252 for advanced Parkinson's disease. The study will evaluate safety, tolerability, pharmacokinetics and preliminary efficacy and is aligned with an FDA 505(b)(2) NDA pathway.
Serina expects a blinded Safety Monitoring Committee review from Cohort 1 enabling advancement to Cohort 2 in 3Q 2026 and will provide ongoing clinical and operational updates as enrollment progresses.
Serina Therapeutics (NYSE American: SER) announced the first patient enrollment in its Phase 1b registrational trial of SER-252 for advanced Parkinson's disease in Australia on Feb 19, 2026. The study will assess safety, tolerability, pharmacokinetics and preliminary efficacy.
The company said it remains on track to begin dosing in Q1 2026 and cited FDA alignment on a 505(b)(2) NDA pathway. Serina noted operational partnerships with Parkinson's Australia and Neuroscience Trials Australia to support enrollment.
Serina Therapeutics (NYSE American: SER) announced a CEO presentation and live Q&A titled “Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences” on Wednesday, February 4, 2026 at 8:30 AM PT / 11:30 AM ET.
CEO Steven Ledger will discuss potential FDA impacts on drug development timelines and review processes; registration is complimentary at New-FDA-Era.TribePublic.com and questions can be submitted to research@tribepublic.com or via Zoom chat.
Serina Therapeutics (NYSE American: SER) announced FDA clearance of its IND application for SER-252, enabling initiation of site‑level and regulatory activities to start a planned Phase 1b registrational study in advanced Parkinson’s disease. The company noted prior FDA feedback and alignment on a 505(b)(2) NDA pathway.
Serina Therapeutics (NYSE American: SER) received a deficiency notice from the New York Stock Exchange for failing to meet continued listing criteria under Sections 1003(a)(i) and (ii). The company reported stockholders' equity of $1.6 million as of September 30, 2025 and incurred losses in three of its four fiscal years ended December 31, 2024. Serina must submit a compliance plan by February 8, 2026 to regain compliance by July 9, 2027 (an 18‑month cure period). If the NYSE American accepts the plan, Serina may remain listed with periodic and quarterly monitoring; if not accepted, delisting proceedings will begin.
Serina Therapeutics (NYSE: SER) appointed Joshua Thomas, Ph.D., as Vice President and Head of Chemistry effective Dec 11, 2025. Dr. Thomas will oversee internal and external chemistry to optimize POZ-based candidates and support translation from discovery through development for lead IND candidate SER-252.
Dr. Thomas brings 13 years of scientific leadership experience at Mersana Therapeutics, plus 2 years as a Serina consultant and Scientific Advisory Board member, and has worked on ADC platforms, STING agonist ADCs, payload and linker design, patents, and publications.